NantKwest’s Vax-DC/MM cell therapy has induced a partial or complete response in 42 percent of relapsed or refractory multiple myeloma (MM) and lymphoma patients in a…
Dragonfly Therapeutics and Celgene have teamed up to develop therapies for multiple myeloma and other blood cancers. The partners will use Dragonfly’s TriNKET immunotherapy…
Genmab announced that its partner Janssen Biotech will launch three novel studies to investigate the effect of Darzalex (daratumumab) in patients with multiple…
Switzerland’s Agency for Therapeutic Products (Swissmedic) has awarded PharmaMar’s Aplidin orphan drug status to treat patients with multiple myeloma, following a similar designation by the U.S. Food…
Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem cell transplant, according to recent…
Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing multiple myeloma, may avoid disease…
Genentech will present results on several approved or investigational therapies for blood cancers, including lymphoma and myeloma, in the upcoming 58th American Society…
Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. The model supports…
PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in combination with Decadron (dexamethasone, an…
The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center are collaborating to launch a new clinical trial studying minimal…